Check your medicine cabinet: Two common prescription drugs, Corlanor and Sensipar, have been recalled. In early June, manufacturer Amgen recalled a total of nearly 1 million bottles of the medications.
Corlanor, a heart failure drug, was recalled due to a potential foreign substance, while Sensipar, for kidney disease, may have deviations from the Current Good Manufacturing Practice (CGMP), which ensures the identity, strength, quality, and purity of drugs.
Food and Drug Administration. Facts About the Current Good Manufacturing Practice (CGMP).
On June 23, the Food and Drug Administration (FDA) gave the recall the second-highest risk level, Class II, meaning the affected medications may cause temporary or reversible effects, but the risk of serious consequences is low.
What to Look For
Corlanor (Ivabradine) Tablets, 5 mg
- Size: 14-tablet bottles, with NDC: 55513-800-99
- Size: 60-tablet bottles, with NDC: 55513-800-60
Corlanor (Ivabradine) Tablets, 7.5 mg
- Size: 60-tablet bottles
- NDC: 55513-810-60
Sensipar (Cinacalcet) Tablets, 30 mg
- Size: 30-tablet bottles
- NDC: 55513-073-30
Sensipar (Cinacalcet) Tablets, 60 mg
- Size: 30-tablet bottles
- NDC: 55513-074-30
Sensipar (Cinacalcet) Tablets, 90 mg
- Size: 30-tablet bottles
- NDC: 55513-075-30
What You Should Do
If your medication is on the recall list, check the FDA’s report for the lot code and expiration date to see if your specific bottle is affected.
If it is, contact your healthcare provider or pharmacist to determine the best course of action. Class II recalls carry safety risks, but suddenly stopping a medication can sometimes be riskier, Jennifer Young, PharmD, BCPS, CSP, lead medication safety specialist at the Institute for Safe Medication Practices, previously told Health.
“While recall notifications can be frightening,” she said, “it’s important to contact your healthcare provider right away for advice before making any changes to your medication routine.”
Disclaimer
Artificial Intelligence Disclosure & Legal Disclaimer
AI Content Policy.
To provide our readers with timely and comprehensive coverage, South Florida Reporter uses artificial intelligence (AI) to assist in producing certain articles and visual content.
Articles: AI may be used to assist in research, structural drafting, or data analysis. All AI-assisted text is reviewed and edited by our team to ensure accuracy and adherence to our editorial standards.
Images: Any imagery generated or significantly altered by AI is clearly marked with a disclaimer or watermark to distinguish it from traditional photography or editorial illustrations.
General Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service. In no event shall South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service.
The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice. The Company does not warrant that the Service is free of viruses or other harmful components.
